多发性骨髓瘤、血液系统恶性肿瘤及免疫抑制剂与皮脂腺癌相关:FDA不良事件报告系统药物警戒研究
该研究基于FAERS数据库1968至2021年数据,采用病例对照分析,识别58例药物相关皮脂腺癌病例。81%病例有免疫抑制剂暴露,20%发生于实体器官移植受者;
要点
- 免疫抑制剂暴露与皮脂腺癌报告比值比升高相关,实体器官移植受者风险突出。
- 沙利度胺和来那度胺与皮脂腺癌报告比值比显著升高。
- 约三成皮脂腺癌病例合并血液系统恶性肿瘤,如来那度胺相关多发性骨髓瘤。
核心结论
- 皮脂腺癌与免疫抑制剂暴露相关,尤其在实体器官移植受者中。
- 相当比例皮脂腺癌病例合并血液系统恶性肿瘤,特别是来那度胺暴露相关的多发性骨髓瘤。
研究设计与样本
- 基于FAERS数据库1968至2021年数据的病例对照分析,计算皮脂腺癌的报告比值比。
- 共识别58例药物相关皮脂腺癌病例。
主要发现
- 81%病例有免疫抑制剂暴露,20%总病例发生于实体器官移植受者。
- 沙利度胺报告比值比22.63(95%CI 5.52-92.72),来那度胺10.86(95%CI 4.93-23.94)。
- 环孢素、他克莫司、托珠单抗、托法替布和鲁索替尼亦与皮脂腺癌报告比值比升高相关。
临床怎么用
- 对使用免疫抑制剂尤其实体器官移植受者,应关注皮脂腺癌筛查。
- 使用沙利度胺、来那度胺等药物者出现皮肤新生物需警惕皮脂腺癌。
- 合并血液系统恶性肿瘤患者皮肤检查时应考虑皮脂腺癌鉴别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sebaceous carcinoma (SC) is a rare skin cancer with significant associated morbidity and mortality. A known association exists between immunosuppression, in particular solid organ transplant patients (SOTR), and SC. However, the comparative reporting odds ratios (ROR) of different immunosuppressive medications and SC are incompletely defined. OBJECTIVES: To examine the relationship between SC and medication exposure in the FDA adverse event reporting system (FAERS). METHODS: Case-control analyses were performed in FAERS from 1968 to 2021 to examine the reporting odds ratios (ROR) for SC. RESULTS: A total of 58 medication-associated SC cases were identified. Immunosuppressant medication exposure was noted in 81% cases, with 20% total cases occurring in SOTR. Medications affecting the TNF- α -IL-1-IL-2-IL-6 inflammatory axis were associated with elevated ROR for SC, including thalidomide (ROR 22.63, 95% CI 5.52-92.72), lenalidomide (ROR 10.86, 95% CI 4.93-23.94), cyclosporine, tacrolimus, tocilizumab, tofacitinib and ruxolitinib. Thirty per cent of cases of SC occurred with an associated haematologic malignancy or dyscrasia, including chronic lymphocytic leukaemia, non-Hodgkin lymphoma and multiple myeloma. CONCLUSIONS: SC is associated with exposure to immunosuppressive medications, especially in SOTR patients. A significant portion of cases with SC had an associated haematology malignancy, in particular multiple myeloma with exposure to lenalidomide.
引用
- Jedlowski PM, DuPont JP. Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system. J Eur Acad Dermatol Venereol. 2023. PMID: 38071595. doi:10.1111/jdv.19703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。